Bifidobacterium adolescentis and use thereof
US-2019112674-A1 · Apr 18, 2019 · US
US11291697B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11291697-B2 |
| Application number | US-201916520359-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 24, 2019 |
| Priority date | Feb 20, 2019 |
| Publication date | Apr 5, 2022 |
| Grant date | Apr 5, 2022 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present disclosure relates to the field of microbial technology, and discloses a probiotic composition and use thereof. The probiotic composition in the present disclosure is consisted of Bifidobacterium adolescentis CCFM8630, Lactobacillus reuteri CCFM8631 and Lactobacillus rhamnosus CCFM1044, whose effect of alleviating metabolic syndrome is significantly better than that of CCFM8630 or CCFM8631 alone or combination of the two, especially in aspects of lowering epididymal fat content, lowering fasting blood glucose level, lowering the area under sugar tolerance curve and lowering contents of serum low density lipoprotein and total cholesterol, improving liver antioxidant capacity and lowering serum IL-1β content, etc. The extent of decrease or increase is increased by 9.62% to 769.62% compared with formulations of a single probiotic or a combination of two probiotics. The combination of three probiotics achieves a significant synergistic effect.
Opening claim text (preview).
The invention claimed is: 1. A probiotic composition, consisting of Bifidobacterium adolescentis CCFM8630 , Lactobacillus reuteri CCFM8631 and Lactobacillus rhamnosus CCFM1044; wherein ratio of viable count of the Bifidobacterium adolescentis CCFM8630, the Lactobacillus reuteri CCFM8631 and the Lactobacillus rhamnosus CCFM1044 is 1:(1-10):(1-10). 2. A method for preparing the probiotic composition according to claim 1 , comprising, respectively inoculating bacteria solutions of Bifidobacterium adolescentis CCFM8630 , Lactobacillus reuteri CCFM8631 and Lactobacillus rhamnosus CCFM1044 to modified MRS culture medium, culturing at 35-37° C. under anaerobic conditions for 18-24h, and collecting thalli; respectively resuspending the thalli with a freeze-drying protective agent so that the content of each thallus is above 10 10 CFU/mL, then culturing the suspension at 37° C. under anaerobic conditions for 40-60 min, drying to obtain freeze-dried bacterial powder of each thallus, resuspending and diluting, and spreading on a plate to determine the viable count in the bacterial powder; and compounding and mixing the freeze-dried bacterial powder of Bifidobacterium adolescentis CCFM8630, the freeze-dried bacterial powder of Lactobacillus reuteri CCFM8631 and the freeze-dried bacterial powder of Lactobacillus rhamnosus CCFM1044 in a certain proportion such that ratio of viable count of the Bifidobacterium adolescentis CCFM8630, the Lactobacillus reuteri CCFM8631 and the Lactobacillus rhamnosus CCFM1044 is 1:(1-10):(1-10). 3. The method according to claim 2 , wherein the modified MRS culture medium (mMRS) is an MRS culture medium that contains 0.05% of L-cysteine hydrochloride; the freeze-drying protective agent is an aqueous solution that contains 100 g/L-150 g/L skimmed milk powder, 30 g/L-100 g/L sucrose and 30 g/L-100 g/L trehalose; and the drying is a vacuum freeze drying that is carried out after pre-freezing at −15 to 20° C. for 8 to 14h. 4. A method for alleviating metabolic syndrome, comprising using the probiotic composition according to claim 1 . 5. The method according to claim 4 , wherein the probiotic composition is in the form of a health care food or a medicine. 6. The method according to claim 5 , wherein the health care food is a microbial agent or a fermented food. 7. A microbial agent containing the probiotic composition according to claim 1 . 8. The microbial agent according to claim 7 , wherein viable count of the probiotic composition is more than 1×10 11 CFU/g.
Bacteria or derivatives thereof, e.g. probiotics · CPC title
Antihyperlipidemics · CPC title
Fermented pulses or legumes; Fermentation of pulses or legumes based on the addition of microorganisms (removing undesirable substances A23L11/30; soy sauce A23L27/50) · CPC title
Free radical scavengers or antioxidants · CPC title
Lactobacilli, e.g. L. acidophilus or L. brevis · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.